NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (242)	1/24/1999 11:56:00 PM
From: Mike McFarland	Read Replies (1) of 613

GLGC...Q&A attack of the bionewbies... First of all from third quarter we have The company had a third-quarter net loss of $37.8 million, or $2.54 per share, including a one-time charge of $35.2 million, or $2.36 per share, for acquisition of in-process research and development. The in-process R&D was obtained through acquisition of Oncormed Inc., which provided Gene Logic with development-stage genomic database and pharmacogenomics technologies. You said something about understanding the progression of disease...I don't really think that is quite what is going on here. In fact, from the vcall tape, you will hear that the discussion was really more about screening out all the useless compounds fast--and getting a lot of the molecular toxicology done up front...but then he did point out that with most genes, the relevent toxicology pathways are unknown--dosing levels unknown etc. Anyway... I am sort of slowly getting the flavor of what tissue based expression is all about...up/down regulated>> differential expression>>screening/running assays on protein classes...but Biology 101 is what is not coming back to me!--diseased tissue has had a major meltdown, it ain't working so maybe you dont want to screen out those compounds which start switching the genes on and off and which are not toxic to diseased tissue. Of course I am oversimplifying this so much that my questions are absurd--presumably these guys already know the genes they are after...they even build them into the chip! We assume the diseased tissue is diseased because it is genetically flawed (??) and there are only 100 or so really important genes (so far) for which you want to be screening compounds--which is why glgc builds it's chip without the other 49,900 data points on it. You want to do very specific things with certain genes-- more elegant than bathing tissue in an IL blocker or cytokine trap huh? Really wild stuff...boy if I would stay off the PC and read my biology text, maybe then I could ask better questions! Maybe I have missed the point entirely and that you are not finding compounds which effect genes--just using that trick to screen for molucules. It just seems like a high point to start at--the cascade of cellular events is so vast, why start at the very top?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next